AcuFocus Inc. raised $65 million in investments and equity financing in support of its Kamra corneal inlay treatment for near vision loss, or presbyopia.
The Kamra device is already on the market in areas in Europe, Asia-Pacific, the Middle East and South America, according to a press release.
It has CE Mark approval in the European Union and is under an investigational device exemption in the U.S.
The inlay is designed to create a "small aperture effect," allowing the eye to see near and intermediate objects more clearly without damaging distance vision.
"Presbyopia is not a disease and cannot be prevented; it is simply the normal aging process of the eye. Previously, there has been no real solution for presbyopia, but I believe that the KAMRA inlay now fills this gap," Minnesota Eye Consultants’ Dr. Richard Lindstrom said in prepared remarks. "With 80 percent of refractive procedures occurring outside of the US, the KAMRA inlay is clearly a global business."
Cowen Healthcare Royalty Partners led the round with $30 million. Existing investors Medtronic, Bausch & Lomb, Accuitive Medical Ventures, Versant Ventures, Carlyle Group and SV Life Sciences also participated.
Here’s a roundup of other dealflow and investment news:
- Tegal invests $300,000 in therapeutic ultrasound maker NanoVibronix
NanoVibronix Inc., a private company developing medical products for therapeutic ultrasound wound care, received a $300,000
from California-based Tegal Corp.
Read more - Bone-building injection maker Radius Health aims for $91 million
Radius Health Inc. closed the second of a three-tranche funding round with a total of $57.3 million raised of a hoped-for $91 million in financing.
Read more - RevolutionEHR aims for $600,000 for optometric electronic health records
Madison, Wisc.-based Revolution EHR is raising $600,000 for its electronic health record system for optometrists.
Read more - Consult A Doctor wins $10K prize at Americas Venture Capital Conference
Out of 100 candidates, Consult A Doctor won the exclusive $10,000 prize as the "Top Global innovative Venture" at the Americas Venture Capital Conference.
Read more
